06 · Advanced treatment Investigational

Renepheresis™

Filter.Replenish.Renew.

Binary Helix's proprietary protocol combines apheresis-based blood filtration with vital factors from young, healthy, screened donor plasma — followed by infusions of regenerative formulas derived from platelet-rich plasma, stem cells and exosomes. Delivered only under clinician supervision, and still under study.

Request a consultation Read the evidence
How it works

One session, three movements.

Each phase is grounded in a distinct line of research. Below, we explain what each is designed to do — and how strong the evidence behind it is today.

Filter phase: plasma passes through a filtration cartridge designed to capture inflammatory mediators, oxidized lipids and other circulating load before being returned. 01 · FILTER PLASMA IN RETURNED TO CIRCULATION DESIGNED TO REDUCE Inflammatory mediators Oxidized lipids Circulating toxic load
Phase 01 Filter

FilterApheresis-based extracorporeal filtration

Blood is drawn through a sterile, single-use circuit. Plasma is separated from blood cells and passed through a filtration system, then returned to circulation. Binary Helix's proprietary filtration technology belongs to the broader family of therapeutic apheresis, the same clinical category as plasma exchange.

  • Designed to reduceInflammatory mediators and cytokines associated with chronic, low-grade inflammation
  • Designed to reduceExcess lipids and oxidized lipoprotein particles
  • Designed to reduceCirculating toxic load — the burden of certain plasma-borne compounds

Why filter? In mice, replacing old plasma with a simple saline-albumin solution improved markers in muscle, liver and brain — suggesting that diluting age-associated factors may matter in its own right.3 A small human study of therapeutic plasma exchange reported changes in biological-age measures.4

What a filter removes varies by person and by filter type. Lowering a substance in plasma does not, on its own, prove a clinical benefit.

Phase 02 Replenish

ReplenishScreened young-donor plasma fractions & blood factors

After filtration, the protocol adds plasma fractions and blood factors from younger, healthy donors who have been screened and tested. Products are sourced from FDA-regulated blood establishments and are used only where legally permitted.

  • Animal rationaleLinking the circulation of young and old mice (heterochronic parabiosis) restored regenerative activity in aged muscle and liver progenitor cells.1
  • Animal rationaleYoung plasma given to aged mice improved measures of synaptic plasticity, learning and memory.2
  • Open debateSpecific candidate factors — GDF11 and TIMP2 among them — have been proposed, but findings have been contested and are not settled.

Young-plasma effects in mice have not been shown to translate to people. The FDA has cautioned against young donor plasma infusions marketed for aging outside of clinical trials.6 See Safety.

Phase 03 Renew

RenewProprietary regenerative formulas

The session concludes with infusions of Binary Helix formulas derived from platelet-rich plasma (PRP), stem-cell–derived products and exosomes — prepared under clinician direction.

  • PRP growth factorsPlatelets concentrate signalling proteins such as PDGF, TGF-β and VEGF, which are involved in tissue repair; composition varies with preparation method.5
  • MSC exosomesExtracellular vesicles released by mesenchymal stem cells carry proteins, lipids and RNA between cells, and are being investigated as signalling therapeutics.7
  • Our approachFormulas are defined per protocol, documented batch by batch, and reviewed by the supervising clinician.

Regulatory status of stem-cell and exosome products varies by product and jurisdiction, and many are not FDA-approved. Binary Helix uses such components only where legally permitted and within governed protocols.

Your session

Twelve weeks, measured end to end.

Treatment is a single day. Understanding what it did takes longer — so follow-up labs are built into the protocol from the start.

  1. 2–4 weeks before
    01

    Consult & screening labs

    A HelixCare clinician reviews your history, medications and goals, and orders screening labs to confirm eligibility.

    • Blood count, metabolic & coagulation panels
    • Infectious-disease screening
    • Baseline biological-age & inflammation panels
    • Informed consent discussion
  2. ~3–4 hours
    02

    Session day

    At a HelixCare Clinic, trained staff run the three phases while monitoring you continuously.

    • Vitals and pre-session check
    • Venous access, filtration & replenishment
    • Regenerative formula infusion
    • Observation before discharge
  3. 24–72 hours
    03

    Recovery

    Most people are advised to rest the day of the session. Your care team tells you what to watch for and how to reach them.

    • Hydration and light activity
    • Access-site care
    • Symptom check-in from the clinic
  4. Weeks 2 · 6 · 12
    04

    Follow-up labs in MyHelix

    Repeat panels at 2, 6 and 12 weeks land in your MyHelix wallet and are reviewed with your clinician against your baseline.

    • Same assays as baseline
    • Clinician review of changes
    • Adverse-event follow-up

Durations are typical and vary by individual and protocol. The number of sessions, if more than one, is determined by the supervising clinician under the governing protocol.

What we measure

If it can't be measured, we don't claim it.

Every Renepheresis protocol tracks the same panel before and after — so you and your clinician can see what changed, and what didn't.

DNA methylationBlood draw

Biological age clocks

Epigenetic clocks estimate biological age from DNA methylation patterns. We report more than one, because different clocks don't always agree — and small changes in one person should be read with caution.

Illustrative MyHelix chart layout: a baseline measurement followed by pending follow-up points at weeks 2, 6 and 12, with a shaded measurement-uncertainty band. Contains no patient data. BASELINE WK 2 WK 6 WK 12 CLOCK ESTIMATE · ILLUSTRATIVE ○ PENDING MEASUREMENT UNCERTAINTY
Illustrative layout only — contains no patient data.
ProteomicsBlood draw

Proteomic inflammation panel

Broad protein panels tracking inflammatory and senescence-associated signalling.

hs-CRPSerum

High-sensitivity CRP

A widely used marker of systemic, low-grade inflammation.

IL-6Serum

Interleukin-6

A cytokine linked to age-associated inflammation, often called "inflammaging".

ApoB · LDL-P · oxLDLSerum

Lipoprotein particles

Particle number and oxidized LDL — detail a standard cholesterol panel misses.

mRNAResearch use

Transcript signatures

Stress-response and repair transcripts from our panel in development.

MyHelixYour wallet

Every result, in one place you control.

Baseline and follow-up panels sync to your MyHelix wallet, sit beside your genomic and wearable data, and are shared only with the clinicians and studies you choose.

Explore MyHelix insights
The science

Promising biology. Early human evidence.

Renepheresis draws on real research — most of it in animals. Here is what that research found, what kind of study it was, and where its limits are.

Animal[1] · 2005

A young systemic environment reactivates aged progenitor cells

In heterochronic parabiosis, aged mice sharing circulation with young mice showed restored regenerative activity in muscle and liver progenitor cells.

Conboy IM, et al. Nature. 2005;433(7027):760–764.
Animal[2] · 2014

Young blood and cognitive function in aged mice

Young blood plasma administered to aged mice improved synaptic plasticity and performance on learning and memory tasks.

Villeda SA, et al. Nat Med. 2014;20(6):659–663.
Animal[3] · 2020

Diluting old plasma with saline-albumin

Exchanging old mouse plasma for saline plus albumin improved markers in muscle, liver and brain — without adding young blood — pointing to the removal of age-associated factors.

Mehdipour M, et al. Aging (Albany NY). 2020;12(10):8790–8819.
Human pilot[4] · 2022

Plasma dilution and human biological age

A small clinical study of therapeutic plasma exchange reported reductions in measures of biological age. Its size and design mean results need confirmation in larger, controlled trials.

Kim D, et al. GeroScience. 2022;44(6):2701–2720.
Review[5] · 2020

Platelet-rich plasma: performance and considerations

Reviews how PRP composition, growth-factor content and preparation methods vary, and how those differences affect therapeutic use.

Everts P, et al. Int J Mol Sci. 2020;21(20):7794.
Review[7] · 2020

The biology and applications of exosomes

A comprehensive review of how exosomes form, what they carry and their potential — and challenges — as diagnostics and therapeutics.

Kalluri R, LeBleu VS. Science. 2020;367(6478):eaau6977.
Regulatory[6] · 2019

FDA caution on young donor plasma infusions

The FDA warned consumers that young donor plasma infusions promoted for aging and other conditions have no proven clinical benefit and carry the risks of any plasma infusion.

U.S. Food and Drug Administration. Safety communication, Feb 19, 2019.

Evidence status

  • Young blood & plasma dilution — animal studies

    Parabiosis, young plasma and plasma exchange in mice.1,2,3

    Substantial · animal onlyMechanisms and key factors still debated.

  • Therapeutic plasma exchange — human aging biomarkers

    Small clinical study.4

    EarlyPromising signals; not yet replicated at scale.

  • Young donor plasma infusion for aging — humans

    Subject of an FDA safety communication.6

    Not establishedNo proven clinical benefit for aging.

  • PRP-derived growth factors — systemic rejuvenation

    Used locally in some musculoskeletal settings.5

    Not establishedSystemic anti-aging use unproven.

  • MSC-derived exosomes — rejuvenation in humans

    Active area of preclinical research.7

    Not establishedRegulatory status varies; many products not FDA-approved.

  • The Renepheresis™ combined protocol

    Filter + Replenish + Renew, as a single protocol.

    Under studyNo completed trial. BH-RENEW is planned.
Safety & eligibility

Not for everyone — and we'll tell you.

Extracorporeal procedures and blood-product infusions carry real risks. Careful screening is the first and most important step.

Medical review

History, medications, prior reactions to blood products and cardiovascular status.

Screening labs

Blood counts, coagulation, metabolic panel and infectious-disease testing.

Informed consent

Risks, alternatives, investigational status and your right to decline or withdraw.

Contraindications

You may not be eligible if you have

  • An active infectionIncluding fever or an unresolved illness at the time of screening.
  • A bleeding or clotting disorderOr anticoagulation that cannot be safely managed around the procedure.
  • Pregnancy or breastfeeding
  • Active cancerIncluding cancer under current treatment.
  • Severe cardiovascular instabilitySuch as unstable angina, a recent heart attack, uncontrolled arrhythmia or blood pressure.
  • Prior severe reactionsTo blood products, anticoagulants used in apheresis, or infusion components.

Not an exhaustive list. Eligibility is decided by the supervising clinician.

Possible adverse effects

What can happen during or after

  • Citrate reactionsTingling around the lips or fingers, or muscle cramps, from the anticoagulant used in the circuit.
  • Low blood pressureDizziness or light-headedness from fluid shifts.
  • Vasovagal reactionsSweating, nausea or fainting, often related to needles or position.
  • Allergic or transfusion reactionsFrom hives or itching to, rarely, severe reactions to donor plasma or infused products.
  • Access-site problemsBruising, bleeding or infection where the needle or catheter is placed.
  • Infection from donor productsReduced by donor screening and testing, but not zero.

Staff are trained to recognise and manage reactions. Adverse events are recorded and reported under the governing protocol.

A note on the FDA and young donor plasma. In February 2019, the U.S. FDA issued a safety communication cautioning consumers against young donor plasma infusions promoted for aging and other conditions outside of clinical trials, noting no proven clinical benefit and the risks associated with plasma infusion.6

Renepheresis™ is delivered only within clinician-supervised, protocol- and IRB-governed settings at HelixCare Clinics, using screened products from FDA-regulated blood establishments where legally permitted. It is not an approved treatment for any disease, and it is not a substitute for care from your own physician.

Questions

Straight answers.

Don't see yours? Ask during a consultation — there's no obligation to proceed.

Is Renepheresis™ FDA-approved?

No. Renepheresis is an investigational, proprietary protocol. It is not approved by the FDA to treat, prevent or cure any disease or condition, including aging. It is offered only within clinician-supervised, protocol-governed settings.

How is it different from standard plasma exchange?

Standard therapeutic plasma exchange removes a patient's plasma and replaces it, usually with albumin. Renepheresis begins with Binary Helix's own proprietary filtration technology, then adds two phases specific to our protocol: replenishment with screened donor plasma factors, and infusion of regenerative formulas.

Will it make me biologically younger?

We can't promise that, and no one should. Animal studies are encouraging and one small human study of plasma exchange reported changes in biological-age measures, but the combined Renepheresis protocol has not completed a clinical trial. What we can do is measure your markers carefully before and after, and review the results with you honestly.

Where do the donor plasma products come from?

From FDA-regulated blood establishments, where donors are screened and donations tested under federal requirements. Donor products are used only where legally permitted in the jurisdiction of the treating clinic.

Are stem-cell and exosome components regulated?

Regulation varies by product and jurisdiction, and many stem-cell and exosome products are not FDA-approved. Your clinician will explain the regulatory status of each component in your protocol during informed consent, and components are used only where legally permitted.

How long does it take, and how many sessions are needed?

A session typically takes about 3–4 hours, plus screening beforehand and follow-up labs at 2, 6 and 12 weeks. Whether more than one session is appropriate is decided by the supervising clinician under the governing protocol.

Is it covered by insurance?

Investigational therapies are generally not covered by insurance. Costs, if any, are explained in full before you consent. Participation in a formal research study may be handled differently — details are provided at enrollment.

Can I join the BH-RENEW study instead?

BH-RENEW is planned and not yet enrolling. You can ask to be notified when enrollment opens using the form below, or follow its status on the Clinical Research page.

Consultation

Start with a conversation.

A HelixCare care coordinator will reach out to arrange a consultation with a clinician, who can help you decide whether Renepheresis — or something else entirely — is right for you.

  • No obligation to proceed
  • Eligibility decided by a licensed clinician
  • Full informed-consent discussion before any procedure
  • Your details used only to respond to your request

See our Privacy Charter for how we handle your information.

References

  1. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005;433(7027):760–764.
  2. Villeda SA, Plambeck KE, Middeldorp J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20(6):659–663.
  3. Mehdipour M, Skinner C, Wong N, et al. Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin. Aging (Albany NY). 2020;12(10):8790–8819.
  4. Kim D, Kiprov DD, Luellen C, et al. Old plasma dilution reduces human biological age: a clinical study. GeroScience. 2022;44(6):2701–2720.
  5. Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;21(20):7794.
  6. U.S. Food and Drug Administration. Important information about young donor plasma infusions for profit. Safety communication, February 19, 2019.
  7. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.

Notes

  • Renepheresis™ is a trademark of Binary Helix Bioscience.

Renepheresis™ is an investigational, proprietary protocol that has not been approved or cleared by the U.S. Food and Drug Administration and has not been evaluated in a completed clinical trial. Information on this page is educational, describes scientific rationale drawn largely from animal research, and is not medical advice. It is not intended to diagnose, treat, cure or prevent any disease. Individual results cannot be predicted and no outcome is guaranteed. Procedures are provided only by licensed clinicians at HelixCare Clinics, within protocol- and IRB-governed settings, using products and components only where legally permitted. Talk to your own physician before making decisions about your health.